ARTA
ORKA

A.R.T. Advisors’s Oruka Therapeutics ORKA Stock Holding History

A.R.T. Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,168
Closed -$75K – 1786
2019
Q3 		$75K Buy
+1,168
New +$85.9K ﹤0.01% 1288

Other funds holding ORKA

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

A.R.T. Advisors's ORKA Position: Q4 2019 in Review

A.R.T. Advisors sold out of Oruka Therapeutics (ORKA) in Q4 2019, closing a stake of 1,168 shares — an estimated $75K sold.

A.R.T. Advisors first reported a position in ORKA in Q3 2019 and held it in 1 quarter. The position peaked at $75K in Q3 2019. 12 funds tracked by Wall St. Rank hold ORKA as of Q4 2019.

  • A.R.T. Advisors reported no remaining Oruka Therapeutics position as of Q4 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 1,168 Oruka Therapeutics shares in Q4 2019, an estimated $75K.
  • A.R.T. Advisors first reported a position in Oruka Therapeutics in Q3 2019 and held it in 1 quarter.
  • A.R.T. Advisors's Oruka Therapeutics position peaked at $75K in Q3 2019.
  • 12 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.